Main Page

• The continuation of beta-blockers on hospitalization for decompensated, systolic heart failure was associated with improved clinical outcomes and that discontinuation of beta-blocker therapy conferred negative clinical outcomes.

September 16, 2008: Drug Eluting Stents are Associated with Reduced Mortality Compared with Bare Metal Stents

• Researchers demonstrate that the implantation of drug eluting stents in the “real world” setting is associated with reduced mortality compared with bare metal stents.

September 16, 2008: Elevated Plasma Fibrinogen Levels among Diabetics and Increased BMI are Associated with Reduced Platelet Inhibition with Clopidogrel

• Investigators have demonstrated that among patients with cardiovascular disease, elevated plasma fibrinogen levels among diabetic patients and elevated body mass index are associated with reduced platelet inhibition with clopidogrel therapy.

September 2, 2008: Intracoronary infusion of selected and unselected mononuclear cells does not lead to significant improvement in cardiac function after sustained ischemia: Results from the REGENT trial

• Intracoronary infusion of bone marrow-derived unselected mononuclear cell (MNC) and selected CD34+CXCR4+ cells does not lead to a significant improvement in LV function, according to researchers from the Myocardial Regeneration by Intracoronary Infusion of Selected Population of Stem Cells in Acute Myocardial Infarction (REGENT) Randomized Multicenter Trial.

September 2, 2008: Ezetimibe and Simvastatin Combination in the SEAS Trial does Reduce Coronary Artery Events but Not the Progression of Aortic Stenosis

• Researchers demonstrate that ezetimibe and simvastatin combination does not halt the progression of aortic valve disease among patients with mild to moderate aortic stenosis.

September 2, 2008: Apixaban causes increased bleeding, but reduced ischemic events in patients with recent acute coronary syndrome: Results of the APPRAISE-1 Trial

• Results of the Dose Ranging Study to Evaluate Safety and Efficacy of Apixaban in Patients with a Recent Acute Coronary Syndrome (APPRAISE-1) demonstrate that administration of the factor Xa inhibitor Apixaban on top of current antiplatelet therapy for 6 months post-acute coronary syndrome (ACS) leads to increased bleeding in a dose-dependent fashion and reduced ischemic events.

September 2, 2008: F.I.R.E. Study Misses Primary Endpoint

• Researchers from Oslo announced that the peptide FX06 failed to meet the FX06 in Ischemia and Reperfusion (F.I.R.E.) Study’s primary endpoint of reduced infarct size.

September 2, 2008: High dose Tirofiban Might be Beneficial among Poor Responders to Clopidogrel and Aspirin Following Elective PCI: Results of the 3T/2R study

• Investigators from Italy reported that for poor responders to clopidogrel and aspirin, treatment with high-dose bolus tirofiban following elective PCI decreased the rates of periprocedural myocardial infarction and 30-day major adverse cardiovascular events compared to placebo.

September 2, 2008: Darapladib A Direct Lipoprotein Associated Phospholipase A2 Inhibitor Reduces Necrotic Core but not Plaque Deformability

• Administration of oral darapladib to patients with coronary artery disease did reduce the necrotic core in coronary atheroma but not plaque deformability and serum high sensitive-CRP levels.

September 1, 2008: SYNTAX study fails to support PCI as non-inferior to CABG in patients with left main or 3-vessel coronary artery disease

• The SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery (SYNTAX) study failed to show that PCI is non-inferior to CABG in patients with left main or 3-vessel coronary artery disease.

September 1, 2008: Fluvastatin XL therapy may prevent adverse cardiac outcomes in patients undergoing major vascular surgery: Results from the DECREASE III trial

• Researchers from the Netherlands reported today an improved postoperative cardiac outcome associated with fluvastatin XL therapy in high-risk patients undergoing vascular surgery.

September 1, 2008: Revascularization with CABG or PCI had no Difference on Outcomes of Death, non-fatal MI, or CVA for Diabetics with Multi-Vessel Coronary Disease: Results of the CARDia Trial

• European investigators reported that for diabetes patients with coronary artery disease, treatment with CABG provided no significant benefit over PCI in terms of the composite variable of death, non-fatal myocardial infarction, and cerebrovascular accident at 1 year.

September 1, 2008: Biolimus Eluting Stents Shown to be as Safe and Effective as Sirolimus Eluting Stents in Everyday Clinical Practice: Results from the LEADERS Trial‎

• Researchers from Europe reported today that the biolimus eluting stent with biodegradable polymer displayed non-inferior efficacy, safety and aniographic outcome at nine months when compared to sirolimus eluting stent with a durable polymer. These results were demonstrated in a non-restricted patient population with mainly off-label characteristics.

August 31, 2008: Intensified NT BNP guided Therapy might be Beneficial among Patients aged less than 75 Years: Results from the TIME-CHF Trial

• Researchers from Switzerland demonstrated that an intensified NT-BNP guided treatment of heart failure did not improve overall outcome but did reduce hospitalization and death among patients aged 60 to 74 years.

August 31, 2008: Rosuvastatin is Not Beneficial Among Patients with Chronic Heart Failure: Results from GISSI-HF trial

• The GISSI-HF trial does not demonstrate a reduction in cardiovascular death or hospitalization associated with rosuvastatin administration among patients with chronic heart failure.

August 31, 2008: BEAUTIFUL study fails to meet primary endpoint but demonstrates that heart rates can safely be reduced with Ivabradine

• Although the BEAUTIFUL study failed to meet its primary endpoint, it demonstrated that among patients with a baseline heart rate >70 BPM, Ivabradine significantly reduced hospitalization for fatal and non-fatal myocardial infarction and the risk of coronary revascularization.

August 31, 2008: GISSI-HF trial suggests long-term treatment with n-3 PUFAs provides moderate clinical benefits for chronic heart failure patients

• Italian investigators found that for chronic heart failure patients, treatment with n-3 polyunsaturated fatty acids (n-3 PUFA) in addition to standard best care practices resulted in lower rates of mortality and cardiovascular-related hospital admissions.

August 31, 2008: TRANSCEND Study Misses Primary Endpoint

• Researchers from McMaster University reported that the angiotensin-receptor blocker (ARB), telmisartan, while well tolerated by patients and associated with a modest reduction in the secondary composite outcome of cardiovascular death, myocardial infarction, and stroke, failed to meet its primary endpoint.

August 21, 2008: The On-Time 2 trial Suggests Benefit with Early Administration of Tirofiban in the Ambulance following Acute Myocardial Infarction.

• Investigators from Europe demonstrate that early administration of high dose tirofiban in the ambulance improves ST segment resolution and clinical outcomes following acute myocardial infarction in the On-Time 2 trial.

August 7, 2008: Larger Versus Smaller Clinical Safety Databases for Regulatory Approval of Drugs.

• A recent extensive statistical analysis from Duke University suggests that large database prior to approval of drugs can be a cost-effective means to reduce adverse events in the post approval phase.

August 1, 2008: Cyclosporine Reduces Reperfusion Injury and Infarct Size Following Acute Myocardial Infarction

• A new preliminary French study suggests the beneficial effect of cyclosporine in reducing reperfusion injury and infarct size during PCI following acute myocardial infarction.

July 22, 2008: Simvastatin and ezetimibe combination does not reduce the rate of progression of aortic valve disease in the SEAS trial

• A press release yesterday on the SEAS trial suggests that intensive cholesterol reduction with simvastatin and ezetimibe combination among patients with mild-moderate aortic stenosis (AS) does not reduce the rate of progression of AS but does appear to reduce the risk of coronary artery disease events.

July 8, 2008: Fibrinolysis Followed by PCI Yielded Similar 1-Year Survival Rates to Primary PCI for STEMI in the French Registry

• The results from the FAST-MI study published online in Circulation suggests that fibrinolysis followed by PCI when initiated early after symptom onset yielded comparable 1-year survival rates to primary PCI for STEMI.

July 2, 2008: Low-risk Women with Unstable Angina and NSTEMI Might be Better off with Medical Therapy than Invasive Treatment

• A meta-analysis suggests that an invasive strategy offered comparable benefits among men and high-risk women following NSTEMI in reducing death, myocardial infarction and re-hospitalization with acute coronary syndrome and recommends conservative strategy for low-risk women.

More News: Click on one of the links below for more news

All News Articles

Acute Coronary Syndromes | Biomarker | Cardiovascular Imaging | CT Surgery | Diabetes | Electrophysiology | General Cardiology | Guidelines | Health Policy | Heart Failure | Hypertension | Interventional | Peripheral Arterial Disease | Prevention | Valvular Heart Disease |

Allergy | Anesthesiology | Cardiology | Dermatology | Ear, Nose & Throat | Endocrinology & Metabolic Disease | Emergency Medicine | GI | Genetics | Geriatrics | Hematology | Infectious Disease | Musculoskeletal | Neurology | Nutrition | ObGyne | Oncology | Ophthalmology | Overdose & Toxicology | Pathology | Pediatrics | Psychiatry | Pulmonary | Radiology | Renal & GU | Rheumatology & Autoimmune | Surgery | Transplant

Contents by Individual Disease | by Differential Diagnosis | by Signs and Sx | by Lab Tests | Drug

WikiDoc Medical School Curriculum: Anatomy | Biochemistry | Biostatistics | Developmental Biology | Epidemiology | Histology | History | Immunology | Medical Ethics | Microbiology | Molecular Biology | Nephrology | NIH | Organic Chemistry | Pharmacology | Physiology | Public Health |

New!

View WikiDoc on your iPhone using the Safari browser!

Check a differential diagnosis, a drug dose or a drug interaction on rounds or in the office!

Cardiology | Dermatology | Ear, Nose & Throat | Endocrinology and Metabolism | Emergency Medicine | GI | Genetics | Ob Gyne | Hematology | Infectious Disease | Musculoskeletal & Ortho | Neurology | Nutrition | Oncology | Opthalmology | Pathology | Psychiatry | Pulmonary | Renal & GU | Rheumatology & Autoimmune

Click Here For WikiPatient

WikiPatient Home Page

Care Centers

Look up a Drug & its side effects

Report a side effect to the FDA at MedWatch

What Was My Doctor Talking About? Watch world experts explain procedures and treatments in language that you can understand

Look up Signs and Symptoms

Weekly EP & ECG rounds at the BIDMC

Click here to put WikiDoc on your iPod